Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Motixafortide pharmacodynamics in multiple myeloma
NCT06547112Phase 1Completed
- Sponsor
- Washington University School of Medicine
- Start
- Oct 2024
- Primary completion
- Jul 2025
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, open-label trial of motixafortide in multiple myeloma (MM) (2 cohorts), sponsored by Washington University School of Medicine. Primary endpoint: Absolute number and relative proportions of CD34+ cell subsets at Day 8. Started Oct 2024; status: completed.
02
Drugs
motixafortide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06547112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06547112.